RARE DISEASERESEARCH ATLAS

ORPHA:2728

Blepharophimosis-intellectual disability syndrome, Ohdo type

medium confidenceDisorder

Also known as: BMRS, Ohdo type · Blepharophimosis syndrome, Ohdo type · Ohdo syndrome · Ohdo-Madokoro-Sonoda syndrome

Publications

219

75th percentile

Trials

0

Interventional, condition-specific

Researchers

1,997

Distinct authors in sample

Gene link

Readiness

1/6

Stages with a signal

Clinical definition (Orphanet)

A multiple syndrome characterized by blepharophimosis, ptosis, dental hypoplasia, hearing impairment and .

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

blepharophimosis syndrome, Ohdo type

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

1/6 stages with a signal

Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    219 matched papers (160 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

219

219 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

219 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

160 in the last 10 years · medium confidence · 75th percentile (publications denominator)

Phrase hits: 219 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,997

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Sadikovic B12 papers · 2025

    Department of Pathology and Laboratory Medicine, Western University, London, ON N6A 3K7, Canada.

    Papers in Europe PMC
  2. 02
    Campeau PM9 papers · 2024

    Department of Pediatrics, Centre de Recherche du CHU Ste-Justine, Montreal, Canada.

    Papers in Europe PMC
  3. 03
    Kerkhof J8 papers · 2024

    Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A 5W9, Canada.

    Papers in Europe PMC
  4. 04
    Levy MA7 papers · 2025

    Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A 5W9, Canada.

    Papers in Europe PMC
  5. 05
    McConkey H7 papers · 2025

    Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A 5W9, Canada.

    Papers in Europe PMC
  6. 06
    Yang XJ7 papers · 2020

    Rosalind and Morris Goodman Cancer Research Center; Departments of Medicine, Biochemistry, and Anatomy & Cell Biology; McGill University; Montréal, QC Canada.

    Papers in Europe PMC
  7. 07
    Gibbs RA6 papers · 2025

    Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX.

    Papers in Europe PMC
  8. 08
    Haghshenas S6 papers · 2024

    Department of Pathology and Laboratory Medicine, Western University, London, ON N6A 3K7, Canada.

    Papers in Europe PMC
  9. 09
    Isidor B6 papers · 2025

    CHU Nantes, Service de Genetique Medicale, Institut de Biologie, Nantes, France.

    Papers in Europe PMC
  10. 10
    Niida Y6 papers · 2025

    Division of Clinical Genetics, Multidisciplinary Medical Center, Kanazawa Medical University Hospital, Ishikawa, Japan.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Blepharophimosis-intellectual disability syndrome, Ohdo type" OR "BMRS, Ohdo type" OR "Blepharophimosis syndrome, Ohdo type" OR "Ohdo syndrome" OR "Ohdo-Madokoro-Sonoda syndrome"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Blepharophimosis-intellectual disability syndrome, Ohdo type" OR "BMRS, Ohdo type" OR "Blepharophimosis syndrome, Ohdo type" OR "Ohdo syndrome" OR "Ohdo-Madokoro-Sonoda syndrome"

Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (219) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium

Ingested 2026-07-26T20:59:44.879Z